Stryker's first quarter 2026 adjusted EPS fell 8.5% on slow growth, but the company reaffirms full-year guidance.

Stryker reported first quarter 2026 net sales of $6.02 billion, a 2.6% increase year-over-year, while adjusted EPS decreased 8.5% to $2.60. Organic sales growth was 2.4% for the quarter, with the company noting an impact from a cyber incident.

Key Highlights

• Organic growth was driven by the Orthopaedics segment, which grew 4.1%, while the MedSurg and Neurotechnology segment saw much slower organic growth of 0.9%.
• Adjusted operating margin contracted by 180 basis points to 21.1%, contributing to the decline in adjusted earnings per share.
• Despite the soft quarter, full-year 2026 guidance was reaffirmed for organic sales growth in the range of 8.0% to 9.5% and adjusted EPS between $14.90 and $15.10.